Investors & Media

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

–  ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated –  ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen –  Study findings warrant further clinical development

Read more
You are now leaving to visit